Page last updated: 2024-11-12

bismuth subcarbonate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID16683095
CHEBI ID31291
SCHEMBL ID1650517
MeSH IDM0091693

Synonyms (38)

Synonym
CHEBI:31291 ,
dibismuth carbonate dioxide
bismuth subcarbonate
2,4-dioxa-1,5-dibismapentane-1,3,5-trione
1,3,5-trioxo-2,4-dioxa-1,5-dibismapentane
2,4-dioxa-1,5-dibismapentane, 1,3,5-trioxo-
einecs 227-567-9
NCGC00165997-01
bismuth subcarbonate (tn)
bismuth subcarbonate (jan/usp)
D01757
5892-10-4
unii-m41l2in55t
m41l2in55t ,
bismuth subcarbonate [usan:usp:jan]
bismuth carbonate oxide (bi2(co3)o2)
tox21_112284
cas-5892-10-4
dtxcid3026518
dtxsid5046518 ,
bismuth(iii) carbonate
AKOS015903495
bismuth carbonate oxide
bismuth(iii) carbonate basic
SCHEMBL1650517
bis(oxobismuthanyl) carbonate
mfcd00010877
bismuth subcarbonate, united states pharmacopeia (usp) reference standard
bismuth(iii) carbonate basic, p.a., 81.0%
1,5-dioxo-2,4-dioxa-1,5-dibismapentan-3-one
Q2983022
dibismuth;oxygen(2-);carbonate
bis((oxobismuthanyl)oxy)methanone
A900951
5892-10-4 , anhydride
bi2o2co3
bismuth subcarbonate (usan:usp:jan)
(bio)2co3

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
bismuth coordination entity
one-carbon compoundAn organic molecular entity containing a single carbon atom (C1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency16.78890.000811.382244.6684AID686979
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency35.48130.035520.977089.1251AID504332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (15.79)18.7374
1990's1 (5.26)18.2507
2000's2 (10.53)29.6817
2010's8 (42.11)24.3611
2020's5 (26.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.80 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index5.29 (4.65)
Search Engine Demand Index95.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (60.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.76%)5.53%
Reviews1 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (90.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]